XTL Biopharmaceuticals Ltd. XTLB
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | -- | -- | -13.65% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | -- | -- | -13.07% | ||
| Operating Income | -- | -- | 13.07% | ||
| Income Before Tax | -- | -- | -32.20% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -- | -- | -32.20% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -- | -- | -32.20% | ||
| EBIT | -- | -- | 13.07% | ||
| EBITDA | -- | -- | 13.08% | ||
| EPS Basic | -- | -- | -32.00% | ||
| Normalized Basic EPS | -- | -- | -300.00% | ||
| EPS Diluted | -- | -- | -44.00% | ||
| Normalized Diluted EPS | -- | -- | -300.00% | ||
| Average Basic Shares Outstanding | -- | -- | 0.00% | ||
| Average Diluted Shares Outstanding | -- | -- | 0.00% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||